News | February 20, 2009

AMI Says Prepare for Changes in PET Coverage Under NOPR

February 20, 2009 - The Academy of Molecular Imaging recommends that PET imaging facilities closely monitor NOPR communications and be prepared for coverage changes on the date the final coverage decision is issued.

On January 6, 2009, CMS proposed significant changes to current coverage regarding Medicare's coverage of PET imaging under NOPR (see http://). Under the proposal, Medicare will provide coverage on a routine basis for many of the indications now reimbursed under NOPR. However, other indications would be covered only under a successor Coverage with Evidence Development (CED) program which likely will be somewhat different than the current NOPR program.

Medicare will publish its final coverage statement on or before April 6, 2009. The new policy becomes effective on the day it is published. The NOPR believes it should be possible to have a successor CED program in place when the NCD is published. However, until the day the new NCD is published, we will not know the details of the final coverage policy, whether any new codes or modifiers must be used for claims, nor whether a successor NOPR program has been cleared by CMS.

Although the new coverage policy will be effective on the day it is published, Medicare Contractors are allowed at least 30 days to implement required changes in their claims processing software, and in
their local coverage policies.

Each site should closely monitor NOPR communications, and be prepared for coverage changes on the date the final coverage decision is issued. In the past, when major coverage or fee schedule changes occurred, some providers have held claims until their contractors have implemented the new edits. As soon as additional information becomes available, we will make it available to participating PET facilities via these e-mail announcements and the NOPR website.

For more information: www.ami-imaging.org and www3.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?id=218

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a

While subject No. 1 (left) was judged as positive for both the neuronal injury and the amyloid load biomarker, both Alzheimer's disease biomarkers were negative in subject No. 2 (right). Image courtesy of Henryk Barthel et al., University Hospital Leipzig, Leipzig, Germany

News | PET Imaging | June 14, 2017
More people die of Alzheimer's disease than prostate and breast cancer combined. Identifying the disease before major...
News | Clinical Study | June 09, 2017
The milestone Imaging Dementia — Evidence for Amyloid Scanning (IDEAS) Study is working with government and academic...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced t
low-dose lung CT scan

An example of a low-dose CT scan of the lungs, showing lung cancer. Image courtesy of Toshiba.

Feature | Lung Cancer | May 05, 2017 | Alison Grimes
The term mesothelioma was coined in 1909, just a few years after the introduction of medical X-ray imaging.
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
April 28, 2017 — Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the devel
Overlay Init